Search Results

There are 11454 results for: content related to: Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial

  1. You have free access to this content
    Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

    Hepatology

    Volume 57, Issue 6, June 2013, Pages: 2155–2163, Mark S. Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, Tarik Asselah, Jean-Michel Pawlotsky, Stephen D. Shafran, Stanislas Pol, Stefan Mauss, Dominique Larrey, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann and Wulf O. Böcher

    Version of Record online : 12 JUN 2013, DOI: 10.1002/hep.26386

  2. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection

    Liver International

    Volume 34, Issue 1, January 2014, Pages: 78–88, Shuhei Nishiguchi, Yoshiyuki Sakai, Makoto Kuboki, Satoshi Tsunematsu, Yasuhisa Urano, Wataru Sakamoto, Yasuhiro Tsuda, Gerhard Steinmann and Masao Omata

    Version of Record online : 15 AUG 2013, DOI: 10.1111/liv.12254

  3. Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation

    The Journal of Clinical Pharmacology

    Volume 55, Issue 4, April 2015, Pages: 467–477, John P. Sabo, Jens Kort, Charles Ballow, Angela D.M. Kashuba, Manuel Haschke, Manuel Battegay, Birgit Girlich, Naitee Ting, Benjamin Lang, Wei Zhang, Curtis Cooper, Drané O'Brien, Eleanore Seibert, Tom S. Chan, Donald Tweedie and Yongmei Li

    Version of Record online : 14 JAN 2015, DOI: 10.1002/jcph.436

  4. Direct-acting antivirals for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Janus C Jakobsen, Emil Eik Nielsen, Joshua Feinberg, Kiran Kumar Katakam, Kristina Fobian, Goran Hauser, Goran Poropat, Snezana Djurisic, Karl Heinz Weiss, Milica Bjelakovic, Goran Bjelakovic, Sarah Louise Klingenberg, Jian Ping Liu, Dimitrinka Nikolova, Ronald L Koretz and Christian Gluud

    Published Online : 6 JUN 2017, DOI: 10.1002/14651858.CD012143.pub2

  5. You have free access to this content
    Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection

    Hepatology Research

    Volume 47, Issue 3, March 2017, Pages: E142–E151, Shuhei Nishiguchi, Yasuhisa Urano, Keiko Suzaki, Atsushi Taniguchi, Joseph Scherer, Kristi L. Berger, Anne-Marie Quinson, Jerry O. Stern and Masao Omata

    Version of Record online : 10 AUG 2016, DOI: 10.1111/hepr.12741

  6. Novel Therapeutic Approaches for Hepatitis C

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 78–88, JS Au and PJ Pockros

    Version of Record online : 19 DEC 2013, DOI: 10.1038/clpt.2013.206

  7. You have free access to this content
    HCV Therapy: The Developmental Pipeline

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 429A–447A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26845

  8. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers

    The Journal of Clinical Pharmacology

    Volume 55, Issue 4, April 2015, Pages: 384–391, David Joseph, Peter Rose, Natalja Strelkowa, Armin Schultz, Jeanette Garcia, Mabrouk Elgadi and Fenglei Huang

    Version of Record online : 8 DEC 2014, DOI: 10.1002/jcph.418

  9. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants

    Journal of Pharmacy and Pharmacology

    Volume 68, Issue 4, April 2016, Pages: 459–466, Jing Wu, Thomas Gießmann, Benjamin Lang, Mabrouk Elgadi and Fenglei Huang

    Version of Record online : 28 MAR 2016, DOI: 10.1111/jphp.12538

  10. You have free access to this content
    HCV Therapeutics: New Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 730A–760A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26858

  11. Structure Elucidation of a Complex Faldaprevir-(±)-α-Tocopherol Addition Product Reveals Reactivity of Common Excipient Vitamin E-TPGS

    Journal of Heterocyclic Chemistry

    Volume 53, Issue 6, November 2016, Pages: 1878–1891, Nina C. Gonnella, Shirley A. Rodriguez, Scott Pennino and Daniel Norwood

    Version of Record online : 29 SEP 2015, DOI: 10.1002/jhet.2502

  12. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study

    The Journal of Clinical Pharmacology

    Fenglei Huang, Kristell Marzin, Rüdiger Koenen, Klaus Peter Kammerer, Natalja Strelkowa, Mabrouk Elgadi, Anne-Marie Quinson and Sebastian Haertter

    Version of Record online : 17 MAY 2017, DOI: 10.1002/jcph.931

  13. You have free access to this content
    Viral Hepatitis

    Journal of Gastroenterology and Hepatology

    Volume 28, Issue S2, October 2013, Pages: 151–177,

    Version of Record online : 10 SEP 2013, DOI: 10.1111/jgh.12365_14

  14. Poster Session I (PI-001–120) Displayed 7:30 am – 2:00 pm Attended 7:30 am – 9:00 am

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue S1, March 2014, Pages: S17–S56,

    Version of Record online : 15 MAR 2014, DOI: 10.1038/clpt.2013.247

  15. Current prospects for interferon-free treatment of hepatitis C in 2012

    Journal of Gastroenterology and Hepatology

    Volume 28, Issue 1, January 2013, Pages: 38–45, Catherine AM Stedman

    Version of Record online : 19 DEC 2012, DOI: 10.1111/jgh.12028

  16. You have free access to this content
    Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

    Journal of Gastroenterology and Hepatology

    Volume 29, Issue 8, August 2014, Pages: 1574–1581, Eric J Lawitz and Fernando E Membreno

    Version of Record online : 29 JUL 2014, DOI: 10.1111/jgh.12632

  17. You have free access to this content
    Open-label phase 2 study of faldaprevir, deleobuvir and ribavirin in Japanese treatment-naive patients with chronic hepatitis C virus genotype 1 infection

    Hepatology Research

    Volume 46, Issue 3, March 2016, Pages: E189–E193, Hiroshi Yatsuhashi, Nobuyoshi Kodani, Hiroyuki Ugai and Masao Omata

    Version of Record online : 18 JUN 2015, DOI: 10.1111/hepr.12535

  18. You have free access to this content
    Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 12, June 2014, Pages: 1363–1375, M. H. Miller, K. Agarwal, A. Austin, A. Brown, S. T. Barclay, P. Dundas, G. M. Dusheiko, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, C. Millson, S. D. Ryder, J. Tait, A. Ustianowski and J. F. Dillon

    Version of Record online : 22 APR 2014, DOI: 10.1111/apt.12764

  19. You have free access to this content
    Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir

    Liver International

    Volume 34, Issue s1, February 2014, Pages: 60–68, Tarik Asselah and Patrick Marcellin

    Version of Record online : 23 DEC 2013, DOI: 10.1111/liv.12424

  20. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin

    Journal of Viral Hepatitis

    Volume 23, Issue 3, March 2016, Pages: 227–231, G. R. Foster, P. Ferenci, T. Asselah, P. Mantry, J.-F. Dufour, M. Bourlière, D. Forton, M. Maevskaya, D. Wright, E. M. Yoshida, J. García-Samaniego, C. Oliveira, M. Wright, N. Warner, N. Sha, A.-M. Quinson and J. O. Stern

    Version of Record online : 17 NOV 2015, DOI: 10.1111/jvh.12485